Share
Richard Ascroft
Sun Pharmaceutical Industries Limited, along with its subsidiaries and/or associated companies, has appointed Richard Ascroft as its new Chief Executive Officer for North America.
Bringing over 30 years of experience in the pharmaceutical industry, Richard has a strong track record in leadership, innovation, and strategic growth. In his new role, he will oversee Sun Pharma’s North American operations, driving the expansion of its diverse portfolio of innovative medicines, generics, and over-the-counter products across the U.S. and Canada. His expertise spans commercial operations, market access, clinical development, and corporate affairs across both U.S. and global markets.
Richard will play a key role in advancing Sun Pharma’s innovative medicines portfolio, which includes upcoming product launches for alopecia areata and squamous cell carcinoma. He succeeds Abhay Gandhi, who significantly contributed to the growth of the North America business. Richard will report directly to Aalok Shanghvi, Sun Pharma’s Whole-Time Director and Chief Operating Officer.
Prior to joining Sun Pharma, Richard served at Takeda Pharmaceuticals as Senior Vice President and Business Unit Head of U.S. Plasma-Derived Therapies, and was part of both the U.S. and global executive leadership teams.
